Company: KROS
Filing Date: 2025-01-21
Form Type: 8-K
Source: 0001664710-25-000008
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-01-21
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On December 3, 2024, Keros Therapeutics, Inc. (the “ Company”) entered into an Exclusive License Agreement (the “ Agreement”) with Takeda Pharmaceuticals U. S. A., Inc. (“ Takeda”), which provides that the Agreement becomes effective upon the expiration or termination of applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act”). The expiration of the applicable waiting period under the HSR Act was on January 16, 2025, and the Agreement became effective on January 16, 2025.

In connection with the effectiveness of the Agreement, Takeda will make an upfront payment to the Company of $200.0 million, as previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 3, 2024.

A copy of the press release announcing the effectiveness of the Agreement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.